Invokana by Mitsubishi Tanabe Explored in New MP Advisors Research Report
Available at Marketpublishers.com
LONDON -- April 16, 2013
Invokana (canagliflozin) belongs within the new class of type 2 diabetes
treatments called selective sodium glucose co-transporter 2 (SGLT2)
inhibitors. Invokana was first developed by Mitsubishi Tanabe Pharma
Corporation in Japan to be later licensed to Janssen Pharmaceuticals. In March
2013, Invokana became the first of SGLT2 inhibitors to receive approval from
the US Food and Drug Administration (FDA).
It is expected that Invokana’s peak sales could breach the USD2.5bn mark,
thought competition in the field will be fierce. Cardiovascular events,
associated genital/urinary tractinfections, compromised efficacy in renally
impaired patients and long-term safety study requirements by the FDA will
limit the initial uptake of Invokana to a small segment of diabetic patients –
those moving to triple oral antidiabetes drugs (OADs), on GLP-1 or Insulin.
The market share among Invokana, Empagliflozin and Dapagliflozin is expected
to be split by about 55:35:10, respectively.
New report “MITSUBISHI TANABE , Outperform - Invokana: Nice to Have A Clean
Label, Yet A Long Way To Go Before Gaining Full Confidence!” developed by MP
Advisors provides an in-depth assessment of Invokana, comparing its efficacy
and safety with analogues, speculating on thetarget patient population,
presenting marketing model of the drug, besides giving insights into SGLT2
pipeline in Japan and globally.
Companies canvassed in the study include: Mitsubishi Tanabe, Johnson &
Johnson, Eli Lilly, and Lexicon.
Title: MITSUBISHI TANABE, Outperform - Invokana: Nice to Have A Clean Label,
Yet A Long Way To Go Before Gaining Full Confidence!
Published: April, 2013
Price: US$ 500.00
More MP Advisors Reports are Also Available:
*AstraZeneca - On the Verge of a Breakdown - Respiratory Portfolio
(Symbicort and Pulmicort) Threatened by Generics
*CADILA HEALTHCARE LTD, Upgrade to Outperform - Best Poised beyond Patent
Cliff - Complex Generics Launches on the Horizon
*RIGEL - SyK Inhibition Not Good Enough - Limited Market Potential!
*VERTEX PHARMA - Dependence on Success of its CF Pipeline = Risk
*BIOGEN IDEC - Hold On - After TECFIDERA Array of Approvals Yet to Come!
More new studies by MP Advisors can be found at
The Market Publishers, Ltd.
Tel: +44 208 144 6009
Fax: +44 207 900 3970
Press spacebar to pause and continue. Press esc to stop.